| Bioactivity | Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD)[1][2]. | ||||||||||||
| Invitro | Teglicar has L-CPT1 inhibitory activity with an IC50 value of 0.68 μM and a Ki value of 0.36 μM[1].Teglicar (10 μM; 2 h) induces a concentration-dependent reduction of ketone bodies and glucose production[1]. | ||||||||||||
| Name | Teglicar | ||||||||||||
| CAS | 250694-07-6 | ||||||||||||
| Formula | C22H45N3O3 | ||||||||||||
| Molar Mass | 399.61 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|